Great news.
It’s great for Neuren and I also think it’s fantastic for Retts sufferers in those regions. Acadia has proven to be a really good partner, and seemingly caring organization to the patient communities - Acadia, although they don’t have a presence outside the US, must view Daybue as their opportunity for expansion - they are obviously extremely pleased with the take up in the states and it also gives them the best chance to ensure the price for the drug won’t be seriously undercut.
Speed to market won’t be compromised from this in my view.
Great news.It’s great for Neuren and I also think it’s fantastic...
-
- There are more pages in this discussion • 5,491 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.61 |
Change
0.010(0.06%) |
Mkt cap ! $1.995B | |||
| Open | High | Low | Value | Volume |
| $15.64 | $15.93 | $15.44 | $8.412M | 538.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 558 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.66 | 1841 | 1 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |